Apex BiotechnologyTPE:1733 -0.17%81 Interest Coverage is 40.82 as of Dec. 2025, which is 59% above its 10-year median of 25.66. GuruFocus rates TPE:1733 with a GF Score™ of 81/100 and a GF Value™ of NT$30.08 (Fairly Valued). The stock has 2 warning signs investors should review. Among 376 Biotechnology companies, Apex Biotechnology ranks worse than 57.45% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Apex Biotechnology's
Operating Income
for the
three
months ended in Dec. 2025 was NT$34 Mil. Apex Biotechnology's Interest Expense for the
three
months ended in Dec. 2025 was NT$-1 Mil.
Apex Biotechnology's interest coverage for the quarter that ended in Dec. 2025 was 40.82.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Apex Biotechnology's Interest Coverage or its related term are showing as below:
TPE:1733'
s Interest Coverage Range Over the Past 10 Years
Min: 10.02 Med: 25.66 Max: 45.76
Current: 45.76
TPE:1733's Interest Coverage is ranked worse than 57.45% of 376
companies
in the Biotechnology industry
Industry Median: 110.86
vs TPE:1733: 45.76
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Apex Biotechnology Interest Coverage Related Terms
Apex Biotechnology Interest Coverage Historical Data
* Premium members only.
The historical data trend for Apex Biotechnology's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
TPE:1733 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Apex Biotechnology's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apex Biotechnology's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apex Biotechnology (TPE:1733) has a Interest Coverage of 40.82 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Apex Biotechnology and its competitors. This is 59% above median its historical median of 25.66. Over the past decade, Apex Biotechnology's Interest Coverage has ranged from 10.02 to 45.76. According to the industry distribution chart, Apex Biotechnology ranks #216 out of 376 companies in the Biotechnology industry, placing it in the top 57.4%.
Is Apex Biotechnology's Interest Coverage too high?
Apex Biotechnology's current Interest Coverage of 40.82 is 59% above median its 10-year median of 25.66. Over the past 10 years, this metric has ranged from a low of 10.02 to a high of 45.76. The Biotechnology industry median Interest Coverage is 110.86. Apex Biotechnology's value of 40.82 is 63.2% below this industry median. Based on the distribution chart, Apex Biotechnology ranks #216 out of 376 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Apex Biotechnology has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Apex Biotechnology ranks #216 out of 376 companies for Interest Coverage. This places Apex Biotechnology in the lower half of its industry. The industry median Interest Coverage is 110.86. Apex Biotechnology's value of 40.82 is 63.2% below this benchmark. Historically, Apex Biotechnology's own Interest Coverage has ranged from 10.02 to 45.76 over the past decade. While the company's 10-year median is 25.66 vs. the industry median of 110.86, Apex Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 110.86, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apex Biotechnology's current Interest Coverage of 40.82 is 63.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Apex Biotechnology and its competitors. For the Biotechnology industry, the median Interest Coverage is 110.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apex Biotechnology's current Interest Coverage is 40.82, which is 59% above median its own 10-year median of 25.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.08, compared to a current price of NT$29.90 — trading 0.6% below its estimated fair value. The current Interest Coverage is 40.82, which is 59% above median its 10-year median of 25.66 and 63.2% below the Biotechnology industry median of 110.86. Apex Biotechnology's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current Interest Coverage is 40.82 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be undervalued.
The current stock price of NT$29.90 is trading 0.6% below its estimated GF Value™ of NT$30.08.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
Interest Coverage: 40.82 (59% above median its 10-year median of 25.66)
GF Value™: NT$30.08 vs. price of NT$29.90 (0.6% below fair value)
Industry Position: 63.2% below the Biotechnology median (#216 of 376)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
81GF Score
Get the complete analysis for TPE:1733
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
